137 related articles for article (PubMed ID: 35704458)
1. Patient Experience and Satisfaction with Opioid-Related Screening and Intervention in North Dakota Community Pharmacies.
Lothspeich E; Werremeyer A; Chase S; Huseth-Zosel A
J Pharm Pract; 2023 Oct; 36(5):1217-1224. PubMed ID: 35704458
[No Abstract] [Full Text] [Related]
2. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose.
Skoy E; Eukel H; Werremeyer A; Strand M; Frenzel O; Steig J
J Am Pharm Assoc (2003); 2020; 60(1):117-121. PubMed ID: 31677933
[TBL] [Abstract][Full Text] [Related]
3. Patient and pharmacist perspectives on opioid misuse screening and brief interventions in community pharmacies.
Rao D; Ford JH; Shiyanbola OO
Addict Sci Clin Pract; 2024 Apr; 19(1):27. PubMed ID: 38589965
[TBL] [Abstract][Full Text] [Related]
4. What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy.
Nielsen S; Sanfilippo P; Picco L; Bruno R; Kowalski M; Wood P; Larney S
Int J Clin Pharm; 2021 Apr; 43(2):420-429. PubMed ID: 32533428
[TBL] [Abstract][Full Text] [Related]
5. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
Thornton JD; Lyvers E; Scott VGG; Dwibedi N
J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
[TBL] [Abstract][Full Text] [Related]
6. Brief intervention medication therapy management: Establishment of an opioid misuse intervention model delivered in a community pharmacy.
Kenney A; Cox N; Bryan MA; Cochran G
Am J Health Syst Pharm; 2021 Feb; 78(4):310-319. PubMed ID: 33386733
[TBL] [Abstract][Full Text] [Related]
7. Community Pharmacists' Knowledge and Perceptions of Buprenorphine for Patients with Opioid Use Disorder.
Tutag Lehr V; Nolan C
J Addict Med; 2023 Jul-Aug 01; 17(4):e224-e231. PubMed ID: 37579094
[TBL] [Abstract][Full Text] [Related]
8. Prescription Opioid Misuse Among Rural Community Pharmacy Patients: Pilot Study for Screening and Implications for Future Practice and Research.
Cochran GT; Engel RJ; Hruschak VJ; Tarter RE
J Pharm Pract; 2017 Oct; 30(5):498-505. PubMed ID: 27402634
[TBL] [Abstract][Full Text] [Related]
9. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a Program to Screen Patients in Community Pharmacies for Opioid Misuse and Accidental Overdose.
Skoy E; Frenzel O; Eukel H; Lothspeich E; Steig J; Strand M; Werremeyer A
Prev Chronic Dis; 2022 Jul; 19():E41. PubMed ID: 35834737
[TBL] [Abstract][Full Text] [Related]
11. Program evaluation of the Opioid and Naloxone Education (ONE Rx) program using the RE-AIM model.
Strand MA; Eukel H; Frenzel O; Skoy E; Steig J; Werremeyer A
Res Social Adm Pharm; 2020 Sep; 16(9):1248-1254. PubMed ID: 31812501
[TBL] [Abstract][Full Text] [Related]
12. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
13. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
14. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
15. Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study.
Nielsen S; Picco L; Kowalski M; Sanfilippo P; Wood P; Larney S; Bruno R; Ritter A
Res Social Adm Pharm; 2020 Dec; 16(12):1694-1701. PubMed ID: 32273255
[TBL] [Abstract][Full Text] [Related]
16. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
Bailey AM; Wermeling DP
Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
[TBL] [Abstract][Full Text] [Related]
17. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
[TBL] [Abstract][Full Text] [Related]
18. Community pharmacist-provided opioid intervention frequencies and barriers.
Nichols MA; Kepley KL; Rosko KS; Hudmon KS; Curran GM; Ott CA; Snyder ME; Miller ML
J Am Pharm Assoc (2003); 2023; 63(1):336-342. PubMed ID: 36369075
[TBL] [Abstract][Full Text] [Related]
19. Assessing pharmacists' readiness to dispense naloxone and counsel on responding to opioid overdoses.
Melaragni F; Levy C; Pedrazzi J; Andersen M
J Am Pharm Assoc (2003); 2019; 59(4):550-554.e2. PubMed ID: 31109812
[TBL] [Abstract][Full Text] [Related]
20. Opioid risk screening: Program evaluation from the community pharmacists' perspective.
Frenzel O; Eukel H; Lothspeich E; Skoy E; Steig J; Strand M; Werremeyer A
J Am Pharm Assoc (2003); 2022; 62(3):859-863.e1. PubMed ID: 34953730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
